Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 161 results for "sarabjit kour nangra"

Tech Mahindra acquires US company for $240m
Times of India

Tech Mahindra acquires US company for $240m

BENGALURU: India's fifth-largest IT services company Tech Mahindra said it will acquire Virginia, US-based Lightbridge Communications Corporation (LCC) for $240 million (over Rs 1,400 crore), making it the largest overseas acquisition it has ever ... Times of India, 4 days ago
TechM buys US network services firm for $240m The Financial Chronicle, 4 days ago

1 images for "sarabjit kour nangra"

Times of India, 3 days ago
Samaylive

Techm Buys LCC For Rs 1486 Cr In Biggest Indian IT Deal This Year

— By | Nov 21, 2014 01:09 am With An Annual Revenue Of About $430 Mn, Lightbridge Communications Will Help The Country's Fifth-Largest Software Services Firm Strengthen Its Presence In The Fast-Growing Telecom And Enterprises Network Market New ...
 The Freepress Journal3 days ago Tech Mahindra to buy LCC for $240 mn in largest Indian IT deal this year  Samaylive3 days ago Tech Mahindra buys US company for 240 million  Hindustan Times3 days ago Tech Mahindra buys LCC for $240 million in largest Indian IT deal this year  DNA India4 days ago
[x]  

Ranbaxy Laboratories : sues FDA for revoking approvals

Mumbai : Ranbaxy Laboratories , the company in waiting to be merged with Sun Pharma, has taken a legal recourse against the US drug regulator for revoking the tentative approvals granted for launching the generic versions of AstraZeneca's heartburn ...
 4 Traders4 days ago Ranbaxy files suit against USFDA for revoking approved drugs  DNA India5 days ago Ranbaxy sues FDA for revoking approvals [DNA : Daily News & Analysis (India)]  Pharmacy Choice4 days ago Double blow to Ranbaxy  Calcutta Telegraph2 weeks ago

US court overturns Ranbaxy bid to block launch of rival generic drugs

In a setback, the US court has denied a request by drug-maker Ranbaxy Laboratories to stop competitors from launching copies of AstraZeneca Plc's heartburn pill Nexium and Roche€s antiviral Valcyte. Ranbaxy had sought the restraining order against ...
 MyIris4 days ago

Ranbaxy sues USFDA for revoking drug approvals

For long at the receiving end, Ranbaxy Laboratories Ltd has chosen to go on the offensive against the United States Food and Drug Administration (USFDA), suing the US regulator for revoking tentative approvals given to it six years ago to launch ...
 Hindu Business Line6 days ago Ranbaxy sues USFDA for revoking approvals for 2 drugs; stk down  Economic Times5 days ago
Business Today India

Cipla shares down 2.4 % post Q2 results

closed down by 2.45 per cent, wiping out Rs 1,228.13 crore from its market valuation, as the company's September quarter results were "below" market expectations. Cipla fell by 2.93 per cent to Rs 605.85 in day trade before closing at Rs 608.85, ...
 Business Standard India1 week ago Cipla shares fall as second quarter numbers disappoint  Business Today India1 week ago Cipla shares fall almost 3% post Q2 results  Hindu Business Line1 week ago
[x]  

Cipla falls 3% post below expected Q2 numbers

S Cipla's scrip lost 2.93 percent to Rs 605.85 at the BSE. At the NSE, it was down 2.67 percent to Rs 606.95. "Cipla posted results for Q2 FY15 below expectations on all fronts," said Sarabjit Kour Nangra, VP Research - Pharma, Angel Broking. ...
 Moneycontrol.com1 week ago Cipla falls 2.93% post Q2 results on below expected numbers  Moneycontrol.com1 week ago
Livemint.com

Sun Pharma's net profit rises 15.4% in Sep quarter

On Thursday, Sun Pharma ended at Rs. 908.60 on the BSE, up 0.26% from the previous close. Photo: Hemant Mishra/Mint New Delhi/Mumbai: India's largest drug maker by revenue Sun Pharmaceuticals Industries Ltd on Thursday reported a 15.4% increase in ...
 Livemint.com1 week ago IPCA's US FDA woes raises huge concern  Business Standard India2 weeks ago IPCA Laboratories stock slumps 16 per cent  Economic Times2 weeks ago IPCA Lab stock slumps 16 per cent  Business Standard India2 weeks ago
[x]  
Financial Chronicle

Aurobindo Pharma to acquire Natrol for $132.5 million

New Delhi: Indian drug maker Aurobindo Pharma Ltd has emerged the highest bidder in a bankruptcy auction of nutritional supplement maker Natrol Inc. and its affiliates. The Hyderabad-based firm made the $132.5 million offer via its US subsidiary ...
 India Brand Equity Foundation1 week ago Aurobindo set to buy Natrol for $132.5 million  Financial Chronicle1 week ago Aurobindo Pharma emerges top bidder to buy Natrol Inc for $132.5 million  Economic Times1 week ago

Dr Reddy's gets FDA approval to launch generic version of Valcyte in US market

Drug maker Dr Reddy's Laboratories today said the company is all set to launch generic version of Valcyte (Valacyclovir Hydrochloride) in the US market soon.Valganciclovir Hydrochloride is prescribed to patients with acquired immunodeficiency ...
 DNA India2 weeks ago Dr Reddy's to launch generic version of Valcyte in US market  The Financial Chronicle2 weeks ago Dr Reddys to launch generic Valcyte in US; shares soar 4.4%  Business Standard India2 weeks ago Dr Reddy's to launch generic Valcyte in US; shares soar 4.4%  Business Standard India2 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less